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Human U87 glioblastoma cells 
with stemness features display enhanced 
sensitivity to natural killer cell cytotoxicity 
through altered expression of NKG2D ligand
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Abstract 
Background: Glioblastoma (GBM) is one of the most lethal tumors with a poor prognosis. Its inevitable recurrence 
is frequently explained by the presence of cancer stem cells. We aimed to show that human GBM cells with stemness 
features are more sensitive to natural killer (NK) cells than GBM cells without stemness characteristics.
Methods: Natural killer cell cytotoxicity was measured using flow cytometry in neurosphere‑forming U87 GBM cells 
cultured with neurobasal media (NBE condition) and compared with that in serum‑cultured U87 GBM cells (serum 
condition). Cytotoxicity was examined after addition of blocking NKG2D monoclonal antibodies. The expression pro‑
file of NK ligands of NK cells were investigated by reverse transcription polymerase chain reaction and western blot 
analysis in the U87 GBM cells in both conditions.
Results: NBE U87 cells showed higher cytotoxicity to NK cells than serum U87 cells did (55 vs 35% at an effector to 
target cell ratio of 5:1). The increased cytotoxicity was diminished in NBE U87 cells by a larger gap than in serum U87 
cells by adding NKG2D blocking antibodies. Of the NKG2D ligands, the expression of ULBP1 and ULBP3 was relatively 
increased in NBE U87 cells compared to serum U87 cells.
Conclusions: U87 GBM cells with stemness features demonstrate increased cytotoxicity to NK cells in association 
with altered NKG2D ligand expression of NK cell activating receptor. Applying immune modulation to GBM treatment 
may be a promising adjuvant therapy in patients with intractable GBM.
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Background
Gliomas comprise a group of central nervous system 
(CNS) tumors with characteristics of neuroglial cells, 
such as astrocytes and oligodendrocytes. Glioblastoma 
(GBM), the most malignant type of glioma [World Health 
Organization (WHO) grade IV], are lethal neoplasms 
with a poor prognosis despite extensive treatments 
involving surgical resection with various combinations of 
radiotherapy, chemotherapy, and possible immunother-
apy [1]. The existence of cancer stem cells in gliomas has 
been pointed out as one of culprits of the resistance of 
the conventional therapies that preludes their metastatic 
spread and recurrence [2]. Many efforts are being made 
to target cancer stem cells, particularly by improving 
immunotherapy using natural killer (NK) cell cytotoxicity 
against the tumors [3].
Natural killer cells can directly kill target cells via the 
perforin-granzyme pathway, antibody-dependent cellular 
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toxicity, and death receptor ligand-induced apoptosis 
[3]. These mechanisms are tightly regulated by a bal-
ance between activating and inhibitory signals; NK 
cells can attack cells with decreased inhibitory signals, 
increased activating receptors, or both. Among them, 
the interaction between NK receptor group 2, membrane 
D (NKG2D) activating receptor and its ligand, such as 
MHC I-related chain (MIC) A/B and UL16 binding pro-
tein (ULBP) 1–5, seem to play a vital role in NK cell cyto-
toxicity [4] against cancer cells as ‘induced self ’, although 
the tumors can secret these ligands as a soluble form to 
evade the immune surveillance.
Natural killer cell-mediated immunotherapy appears 
to be a promising approach to target various origins of 
cancer stem cells. GBM stem-like cells are sensitive to 
activated NK cells [5, 6]. NK cells activation has also been 
studied to enhance its efficacy by co-culture of geneti-
cally engineered K562 feeder cells in cytokine-containing 
medium [7, 8]. Additionally, the U87 GBM cell line has 
been extensively characterized immunologically [9].
The collective evidence indicates the merit of maximiz-
ing NK cell cytotoxicity against GBM with stem cell char-
acteristics. However, the mechanism of NK cell cytotoxicity 
difference between GBM cells with stem cell-like features 
and serum-cultured GBM cells is not clear. In this study, 
we compared NK cell cytotoxicity against neurosphere-
forming U87 cells (NBE U87) and serum-cultured U87 cells 
(serum U87). The mechanism that leads to the differential 
NK cell cytotoxicity between NBE U87 and serum U87 
cells was explored in terms of NK cell degranulation and 
NKG2D–NKG2D ligand (NKG2DL) interaction.
Methods
Cell lines and cell cultures
The U87 human GBM cell line, as reported as isocitrate 
dehydrogenase (IDH)-wild type and O6-methylguanine-
DNA methyltransferase (MGMT) promoter methylated [10, 
11], was obtained from the Korean Cell Line Bank (Seoul, 
Korea). U87 cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM; GibcoBRL, Gaithersburg, MD., 
USA) supplemented with 10% fetal bovine serum (FBS; Gib-
coBRL) at 37 °C in a humidified 95% air and 5% CO2 atmos-
phere, termed here ‘serum’ conditions. U87 cell line was also 
cultured with serum-free neurobasal medium (Invitrogen, 
Carlsbad, CA, USA) containing 50  ng/mL of both basic 
fibroblast growth factor (FGF; PeproTech, Rocky Hill, NJ, 
USA) and epidermal growth factor (EGF; PeproTech) sup-
plemented with N2 and B27 supplement without vitamin A 
and l-glutamine, which are termed ‘NBE’ conditions.
Cytokines and antibodies
Recombinant human interleukin (IL)-2, IL-15 and IL-21 
(PeproTech) were used to expand NK cells. Fuorescein 
isothiocyanate (FITC)-conjugated anti-human CD3 and 
phycoerythrin (PE)-Cy5-conjugated antihuman CD56 
antibodies were used to evaluate the purity of expanded 
NK cells. Anti-human NKG2D antibody was used to 
block the NK cell receptor. PE-conjugated anti-human 
CD107a antibody was used as a surrogate marker of 
degranulation. All the antibodies were from BD Bio-
sciences (San Jose, CA, USA).
Flow cytometry‑based NK cytotoxicity assay
Flow cytometric cytotoxicity assay using calcein acetoxy-
methyl ester (CAM)-stained expanded NK cells were per-
formed as previously described [12]. U87 target (T) cells 
were prepared in serum and NBE conditions. Propidium 
iodide (PI) was added to detect target cell death. The gen-
eration of ex  vivo expanded NK cells was performed as 
described previously, with a slight modification [8, 13, 
14]. Peripheral blood mononuclear cells (PBMCs) were 
co-cultured with 100  Gy gamma-ray irradiated K562 
(ATCC), in a 24-well tissue culture plate in the pres-
ence of IL-2 and IL-15 (PeproTech) in complete RPMI 
(Roswell Park Memorial Institute) 1640 medium. The 
target cells and effector cells were co-cultured at effector-
to-target (E:T) ratios of 10:1, 5:1, and 1:1 for 4 h at 37 °C 
in a humidified incubator containing 5% CO2. Cells were 
acquired by means of FACSCalibur (BD Biosciences) and 
the data were analyzed by BD CellQuest™ Pro Software 
(BD Biosciences). This study was approved by the institu-
tional review board of the Chonnam National University 
Hwasun Hospital (CNUHH-2016-074).
CD107a degranulation assay
Degranulation of expanded NK cells against target GBM 
cells was assessed as previously described [14]. Enhanced 
NK cells were incubated with serum U87 and NBE U87 at 
an effector/target ratio of 10:1 and 5:1 for 1 h in a 96-well 
plate in the presence of 5  µL/mL PE-conjugated anti-
human CD107a. After 1 h, monensin and brefeldin A (BD 
Biosciences) were added and the plate was incubated for 
an additional 4 h. After co-culture with target GBM cells, 
expanded NK cells were washed and stained with FITC-
conjugated anti-human CD3 antibody and PE-Cy5-con-
jugated antihuman CD56 antibody on ice for 15 min. The 
cells were washed, fixed and then analyzed with the use 
of a FACSCalibur instrument.
Cytotoxicity assay after anti‑NKG2D antibody treatment
Anti-human NKG2D antibody was used to block the acti-
vating receptor NKG2D on NK cells. In blocking experi-
ments, anti-NKG2D antibodies were added to the NK 
cell suspension at 10  μg/mL and incubated at 37  °C for 
30 min before the addition of target cells. The number of 
dead cells was estimated by measuring the fluorescence 
Page 3 of 9Oh et al. Cancer Cell Int  (2017) 17:22 
intensity in medium. The fluorescence intensity in 
medium released spontaneously from target cells and the 
total maximum fluorescence intensity released from all 
target cells by treatment with 1% Triton X-100 were also 
determined.
Reverse transcription polymerase chain reaction (RT‑PCR)
Reverse transcription polymerase chain reaction was 
performed as previously described on 23 NK ligands 
[15]. Briefly, total RNA from cells was extracted using 
Trizol reagent (Invitrogen, Carlsbad, CA, USA). An 
adequate amount of RNA was reverse transcribed 
using LeGene Express 1st Strand cDNA Synthe-
sis System Kit (LeGene Biosciences, San Diego, CA, 
USA). Primer sequences used in this study are listed 
in Table  1 [16]. PCR amplification of cDNA was per-
formed using gene-specific primers and h-Taq DNA 
Polymerase (SolGent, Daejeon, South Korea) under the 
following conditions: 15 min of denaturation at 95 °C, 
followed by 35 cycles of denaturation for 30 s at 95 °C, 
annealing for 40  s at 54  °C, and extension for 40  s at 
72 °C, followed by a final extension for 7 min at 72 °C. 
PCR cycles were limited to 35. Primers for endogenous 
reference gene (glyceraldehyde-3-phosphate dehydro-
genase, GAPDH) were used as internal controls. PCR 
products were analyzed by electrophoresis on agarose 
gels containing ethidium bromide. The intensity of the 
bands were quantified by the Labworks Image Acquisi-
tion (UVP, Upland, CA).
Western blotting
Total cellular proteins were extracted from cultured 
cells using RIPA Buffer (Biosolution, Korea) supple-
mented with protease inhibitor Cocktail (Roche, Ger-
many). Briefly, lysates were cleared by centrifugation at 
12,000 rpm for 30 min at 4  °C. Supernatant containing 
proteins were collected for immunoblotting, extracted 
proteins (20–40  μg) were separated by SDS-PAGE 
(6–15%) gel and then electroblotted onto Polyvinylidene 
Fluoride (PVDF) membranes (Amersham Hybond-P, 
Table 1 NK ligand primers used for RT-PCR
CRACC CD2-like receptor activating cytotoxic cell, DNAM-1 DNAX accessory molecule-1, ICAM-1 intercellular adhesion molecule 1, LFA lymphocyte function-associated 
antigen, MIC MHC I-related chain, NK natural killer, NKG2D NK receptor group 2; membrane D, PVR-1 poliovirus receptor-1, RT-PCR real-time quantitative polymerase 
chain reaction, TNF tumor necrosis factor, TRAIL tumor necrosis factor-related apoptosis-inducing ligand, ULBP UL16 binding protein
NK receptor Ligands Forward primer Reverse primer Amplicon size (bp)
NKG2D MICA TCTACTACGATGGGGAGCTCTT ACTGGGGCATTGTCCATTC 66
MICB CTGAGAAGGTGGCGACGTA CGAAGACTGTGGGGCTCA 111
ULBP‑1 TGGGGGATTGTAAGATGTGG GGCCAGAGAGGGTGGTTT 83
ULBP‑2 CCGCTACCAAGATCCTTCTG TGACGGTGATGTCATAGCAAA 105
ULBP‑3 AGGAAGAAGAGGCTGGAACC CTATGGCTTTGGGTTGAGCTA 70
ULBP‑4 GGGAGAATTGACCCAAACG CTTGCAGAGTGGAAGGATCAC 104
NKG2A/C/E/H HLA‑E GGAGTGGCTCCACAAATACC GTCAGAGATGGGGTGGTGAG 94
2DL4 HLA‑G CTGGAGAACGGGAAGGAGAT GGGTGGCCTCATAGTCAAAG 88
2B4 CD48 CCTACATCATGAGGGTGTTGAA ATGACAGGCTTGGGTACAGG 91
NTBA NTBA CCACAATTAATCATTCCAAAGAGA TGTCATTCCCGAATTCCTCT 107
LIR2 HLA‑F ATCACCCAGCGCTTCTATGA CTGGGGAGACTGCTCTGC 138
NKR‑P1A LLT‑1 GTTCAGGGCCAGTGCATATT GACTCTGCACCTTCCTTCACA 61
DNAM‑1 PVR‑1 CAACGTCACCAATGCCCTA CTGAGTGCTCACTGGGAGGT 80
PVR‑2 GATATCTGGCTCCGAGTGCT TCCAGTGAGCTGGACCTTCT 69
Nectin2‑1 GGCAGAGGAGGACGAAGAC GAGCTGGGAGGGCATCTC 94
Nectin2‑2 GAGGACGAGGGCAACTACAC GGCCTCAGCTTGGTTCTTG 108
CD100 CD72 TTCTTCACATGCGGCTCA AGCAGCTTTTCTGATGCATTATC 67
CD28 CD80 TCCTGGGCCATTACCTTAATC CATCTTGGGGCAAAGCAG 77
LFA‑1 ICAM‑1 CCTTCCTCACCGTGTACTGG AGCGTAGGGTAAGGTTCTTGC 90
LFA‑2 LFA‑3 CATGTATTGTGCTGTATATGAATGGT TCTGGCTTCCCAAGTAATGG 141
CRACC CRACC TCTACTATGTGGGGATATACAGCTCA TTTAGGCTTTGACAGGTGCTC 92
FasL Fas GTGGACCCGCTCAGTACG TCTAGCAACAGACGTAAGAACGA 112
TRAIL DR4 GGGTCCACAAGACCTTCAAGT GGGTCCACAAGACCTTCAAGT 68
DR5‑1 GTGTGTCAGTGCGAAGAAGG GACCATCCCTCTGGGACA 90
DR5‑2 GCACCAGGTGTGATTCAGG CCCTCTGGGACACCCTGT 143
TNF TNFR1 CTCTCCACCGTGCCTGAC CCAGTCCAATAACCCCTGAG 85
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GE-Healthcare Life Science, Pittsburgh, PA, USA). Fol-
lowed by transfer membranes were blocked with 5% w/v 
skim milk in TBST (TBS; 0.05 M Tris, 0.15 M NaCl, pH 
7.6 and 0.1% Tween20) for 1  h and then probed with 
primary antibodies diluted in 3% BSA in TBST for over-
night. Membranes were washed in TBST and then incu-
bated with HRP-conjugated anti-mouse or anti rabbit 
secondary antibodies. Membranes were detected with 
an electrochemiluminescence (ECL) system (Millipore). 
The bands were visualized by Luminescent image ana-
lyzer (FUJIFILM, LAS-4000). The following antibodies 
were used: ULBP1 (1:500, sc-33564, Santa cruz biotech-
nology, Dallas, TX, USA), ULBP3 (1:300, sc-390844, 
Santa cruz biotechnology).
Statistics
GraphPad Prism version 6.00 software program for 
Windows (GraphPad, La Jolla, CA, USA) was used to 
analyze the experiments, with the data presented as the 
mean ± the standard error of the mean (SEM). Statistical 
significance was defined at P < 0.05.
Results
NK cell cytotoxicity to NBE and serum U87 GBM cells
To determine whether GBM cells with stem cell char-
acteristics (NBE U87) were more susceptible to NK cell 
cytotoxicity than serum U87 cells, we co-cultured effec-
tor NK cells with each corresponding NBE U87 and 
serum U87 cell lines (Fig.  1a). Assays were performed 
Fig. 1 Representative flow cytometry view and cell compartment. a Forward scatter profiles were used to discriminate target and effector cells 
before (upper panels) and after (lower panel) co‑culture of effector cells (NK cells) and target cells (U87 GBM cells). b Effector NK cells enhanced lysed 
target cell compartments in neurobasal medium‑cultured NBE U87 cells (NBE U87) compared to serum‑cultured U87 cells (serum U87) proportion‑
ally according to decreasing order of E:T ratio. c The average cytotoxicity levels are shown in decreasing order of E:T ratio, representing increased 
cytotoxicity of NK cells in NBE U87 cells compared to serum U87 cells. Bar graphs show the mean ± the standard error of the mean (SEM). (*P < 0.05, 
***P < 0.001)
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in triplicate under serum and NBE conditions with 
E:T ratios from 10:1, 5:1, to 1:1 for expanded NK cells 
(Fig.  1b, c). Both cell lines showed increasing cell lysis 
proportional to increasing amount of effector NK cells. 
NBE U87 cells were, however, more sensitive than serum 
U87 cells to enhanced NK cells, with median cytotoxicity 
at 5:1 effector/target ratio of 56.1 and 34.5%, respectively 
(P < 0.001).
NK cells cytotoxicity with regard to CD107a degranulation
We investigated the relationship between CD107a-
mediated degranulation and NK cell cytotoxicity to 
U87 tumor cells in each group. Using flow cytometry, 
we differentiated subsets of NK cells with CD56+CD3− 
then those with CD107a+ in each co-cultured cell lines 
(Fig. 2a). However, the lower fraction of the CD107a+ 
NK cells was observed in NBE U87 than in serum U87, 
19.7 and 24.9% respectively at a 5:1 effector/target 
ratio (Fig.  2b, P  <  0.05). CD107a+ was not increased 
with a higher effector/target ratio. Contrary to the 
hypothetical expectation, fractions of CD107a+ NK 
cells with degranulation did not appear to explain the 
differential cytotoxicity between NBE U87 cells and 
serum U87 cells.
NK cells cytotoxicity via NKG2D–NKG2DL interaction
Next, we measured NK cell cytotoxicity to tumor cell 
lines by directly neutralizing NKG2D receptor by 
NKG2D antibody. It was apparent that NKG2D blocking 
decreased NK cell cytotoxicity in both cell lines, but with 
Fig. 2 Comparison of the percentage of NK cells characterized by CD107a+ phenotype. a The purity of expanded NK cells were evaluated upon 
immunostaining as CD3−CD56+ cells and the percentage of CD107a+ NK cells were assessed by flow cytometry in both NBE U87 cells and serum 
U87 cells. b Serum U87 cells showed higher fraction of CD107a+ NK cells than NBE U87 cells did. Bar graphs show the mean ± the standard error of 
the mean (SEM). (*P < 0.05)
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a larger decrease in NBE U87 than serum U87 (Fig. 3a). 
The reduction of cytotoxicity was higher in NBE U87 
than serum U87 with blocking NKG2D receptor with sta-
tistical significance at 1:1 of E:T ratios (Fig. 3b, P < 0.05).
Expression of NK ligands by RT‑PCR and western blot
Since the cytotoxicity was decreased by a larger gap in 
NBE U87 cells than in serum U87 cells after applying 
NKG2D blocking antibodies, the expression of causal 
NKG2D ligands and other K cell ligands on the tumor 
cell surfaces were explored. Serum U87 and NBE U87 
cell lines exhibited different RNA profiles of NK ligands 
(Fig.  4). In NBE U87, the expression of NKG2D ligands 
including ULBP1 and ULBP3 were relatively increased 
(Fig.  5a, P  <  0.01 in ULBP1 and P  <  0.05 in ULBP3). 
FAS expression was also increased with marginal sta-
tistical significance. In contrast, the level of DNAX 
accessory molecule-1 (DNAM-1) ligands of poliovirus 
receptor (PVR)-1, PVR-2, Nectin 2-1, and Nectin 2-2 
were decreased in NBE cells (Fig. 4). The enhanced pro-
tein levels of ULBP1 and ULBP3 were also confirmed 
(Fig. 5b, P < 0.05 in both ligands).
Discussion
In the present study, human GBM cells with stem cell-
like features (NBE U87) showed increased cytotoxicity 
to enhanced NK cells compared to serum-cultured GBM 
cells (serum U87). It was also suggested that increased 
cytotoxicity was mediated by NKG2D–NKG2DL interac-
tion supported by different NK cell cytotoxicity in each 
groups after applying NKG2D blocking antibodies. In 
addition, NKG2DL expression in NBE U87 was altered 
in comparison of that in serum U87. Interestingly, we 
observed that the mechanism of different NK cell cyto-
toxicity with regard to stem cell-like features was not due 
to degranulation. As previously reported characteristics 
of U87 cell line, this study is focused on IDH-wild type 
GBM.
Activated NK cells are capable of killing different types 
of cancer cells including glioma cells [5–7]. Once NK cells 
are activated by various means including IL-2, IL-15, or 
PHA, they can overcome immune escape of glioma, such 
as HLA class I molecules, by overwhelming the activat-
ing signals [5, 6]. We used K562 cells in the presence of 
IL-2 and IL-15 to activate NK cells [7]. A previous study 
demonstrated that GBM cells with stem cell-like features 
were susceptible to lysis by lymphokine-activated NK 
cells [6], in contrast to the NK cell resistance caused by 
use of glioma cells cultured under non-stem cell condi-
tions or freshly isolated NK cells [6].
In the current study, NKG2D–NKG2DL interaction 
played a significant role in enhanced NK cytotoxic-
ity against glioma cell lines. Prior studies reported con-
troversial results on the mechanistic cause of increased 
cytotoxicity of tumor cells with stem cell features com-
pared to serum-cultured tumor cells. Glioma is vulner-
able to NK cells via NKp44, NKp46 [5], or DNAM-1 
receptors [6] and their cytotoxicity is considered minimal 
or to be minor via NKG2D. Proneuronal GBM cancer 
stem cell lines were reported to downregulate NKG2D 
expression on NK cells through transforming growth 
factor-beta-dependent suppression, providing an expla-
nation for the reduced immune infiltration [17]. The level 
of NKG2DL expression in tumor cells does not appear to 
correlate with increasing cytotoxicity [9]. The discrep-
ancy between the current study and previous reports can 
be speculated as previously pointed out [5]; the target 
cells used (U87 immortalized GBM cell line vs. primary 
cultured cell lines from GBM patients); methodologi-
cal modification in generating enhanced NK cells (use of 
K562 feeder cells), cytokine concentration, duration of 
Fig. 3 GBM cell sensitivity to NK cell lysis that occurs via NKG2D–
NKG2DL interactions. a Cytotoxicity assays showing that GBM cells 
are sensitive to NK‑mediated cell elimination using NKG2D block‑
ing antibody at different E:T ratio. b Comparison of reduction rate 
between NBE U87 cells and serum U87 cells. The result showed that 
NK‑mediated cell elimination effect using NKG2D blocking antibody 
is greater in NBE U87 cells, suggesting that the different cytotoxicity is 
mediated by NKG2D–NKG2DL interactions
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cytokine treatment); or the effector cells used (polyclonal 
MelanA specificT cell lines vs. enhanced NK cells after 
separation from PBMCs of healthy donors).
However, there have been some subtle points that sug-
gest a mechanistic possibility similar to our results. Jung 
et al. [9] demonstrated the increased expression levels of 
NKG2D ligands in NBE U87 cells, similar to our results. 
Avril et al. showed mRNA analysis results that displayed 
expression of NKG2D ligands [5] and Di Tomaso et  al. 
[18] also reported more commonly detectable MICA, 
ULBP-2, ULBP-3, and ULBP-4, although at a low levels. 
Also, the interaction between NKG2D and DNAM-1 on 
the surface of NK cells with their ligands on tumor cells 
was designated to be critical for NK cell cytotoxicity 
against sarcoma cells as well [7].
Presently, we discovered that the ligands of activat-
ing receptors of NK cells differ from NBE U87 to serum 
U87. Although the level of NKG2DL does not necessarily 
affect NKG2D mediated cytotoxicity with enhanced NK 
cells [9], NBE U87 showed increased cell lysis compared 
to serum U87. High expression of MICA and ULBP2 in 
both cell lines could result in basal cytotoxicity, whereas 
Fig. 4 Expression of NKG2D ligands in serum U87 and NBE U87 GBM cells by RT‑PCR. Increased expression levels are shown in ULBP1, ULBP3, and 
FAS (in bold italic). In comparison, the expression levels reduced in PVR‑1, PVR‑2, Nectin 2‑1, and Nectin 2‑2 (in gray bold italic)
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the increment of ULBP1 and 3 may contribute to rela-
tively higher cytotoxicitiy in stem cell-like GBM.
Additionally, stem cell-like glioma may display hetero-
geneous NK cell ligands depending on different subtypes. 
NBE U87 GBM cell line used in this study showed dif-
ferent RNA profile compared to other studies. Castri-
coni et al. [6] showed increased expression of DNAM-1 
ligands, PVR and nectin-2, in GBM grown in neuroba-
sal medium whereas we observed decreased amounts of 
these ligands in NBE U87. In this sense, the various types 
of glioma could make it difficult to exploit uniformly 
enhanced NK cells and individualized immunotherapy is 
much desired.
It is interesting to note that NK cell cytotoxicity did 
not attribute to the degree of degranulation. Low level of 
CD107a+ fraction in degranulation assay reflects the fact 
that enhanced NK cell cytotoxicity does not result from 
perforin granzyme release. This result implies that NK 
cell activation with NKG2D provides different mecha-
nisms to lyse target cells, such as inducing apoptosis or 
mediating other cytokines.
Enhanced NK cells provided promising results in elimi-
nating many different tumor cell lines [7, 8]. Although NK 
cell cytotoxicity is lower in glioma cell lines than other 
types of tumors, it is still necessary to show improved 
cytotoxicity compared to conventional methods [5, 6]. 
Whether the different cytotoxicities among various 
tumor types are due to different NK cell ligands expres-
sion is uncertain. However, many experiments have 
shown that NKG2D ligands induction in different tumors 
including glioma cell lines give a rise in increased cell 
lysis [19–22], indicating that enhanced NK cell ligands in 
tumor cells do play role in increasing cytotoxicity.
Recent emerging evidence has supported the potential 
synergistic effects of therapeutic combinations against 
solid tumors [3]. Examples include combining NK cell 
therapy with radiation therapy or with monoclonal anti-
body therapy. Radiation-induced tissue injury increases 
the expression of NK activating ligands, such as NKG2D, 
and monoclonal antibody therapy allows NK cells to kill 
antibody-coated target cells through antibody-dependent 
cellular cytotoxicity.
Conclusion
The results indicate that enhanced NK cell cytotoxic-
ity against GBM stem cell populations in combination 
with other conventional anti-cancer therapy may be a 
promising treatment option in the near future. Further 
investigation is needed to elucidate the true nature of the 
enhanced sensitivity to GBM cell with stemness features 
by enhanced NK cells.
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